Chinese Traditional and Herbal Drugs
|
2025, 56(9): 3197-3202
Retrospective clinical study on Qingke Pingchuan Granules in treatment of bronchiectasis
Full
FAN Yaxin1, BAI Ping2, WANG Yu1, MA Shuangshuang1, ZHANG Yemin1, BI Rongrong1, WU Dingzhong1, ZHANG Huiyong1, QIU Lei1
Affiliations
1 Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China;
2 Xinhua Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
doi: 10.7501/j.issn.0253-2670.2025.09.017
Outline
Objective To investigate the curative effect of Qingke Pingchuan Granule combined with conventional Western medicine in the treatment of bronchiectasis and its effect on the acute exacerbation of bronchiectasis patients after discharge. Methods A retrospective analysis was performed on 122 patients with bronchiectasis discharged from the pulmonary Department of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from February 2021 to June 2023, and they were divided into treatment group (n = 61) and control group (n = 61) according to different treatment regiments. The control group only received conventional Western medicine treatment after discharge, the course of treatment was one week; and the treatment group combined with Qingke Pingchuan granules on the basis of the control group. The course of treatment of Qingke Pingchuan granules was eight weeks. The patients were followed up for 24 weeks after discharge. The proportion of acute exacerbations within 24 weeks after discharge, St. George's Respiratory Questionnaire (SGRQ) scores and pulmonary function indicators at baseline and 24 weeks after enrollment were compared between the two groups, and adverse events were recorded. Results The total effective rate of the treatment group was 65.6%, and that of the control group was 44.3%. The difference was statistically significant (P < 0.05). Within 24 weeks after discharge, the rate of acute exacerbations in the treatment group was lower than that in the control group (19.7% vs 36.1%, P < 0.05). Compared with the control group, the time of recurrence of acute exacerbations in the treatment group was longer [(157.18 ±44.07) d vs (137.23 ±57.14) d, P < 0.05]. At the 24 weeks after enrollment, SGRQ scores (symptoms, activities, psychological scores and total scores) in both groups were lower than those at baseline (P < 0.05). The improvement value of SGRQ activity score in the treatment group was higher than that in control group (P < 0.05). At the 24 weeks after enrollment, the pulmonary function indexes (FEV1, FVC, FEV1/FVC) of the two groups were higher than those at baseline, and the difference was no significant difference (P > 0.05). There was no significant difference in the improvement value of lung function between the treatment group and the control group (P > 0.05). There was no significant difference in the incidence of total adverse reactions between the two groups (P > 0.05). Conclusion Qingke Pingchuan Granule combined with conventional Western medicine regimen can effectively reduce the risk of re-acute exacerbation in patients with bronchiectasis within 24 weeks after discharge, help improve chronic respiratory symptoms and mobility, and has a good safety.
bronchiectasis
/
acute exacerbation
/
Qingke Pingchuan Granule
/
Chinese patent medicine
/
SGRQ score
/
lung function
樊雅欣, 柏萍, 王钰, 马双双, 张晔敏, 毕蓉蓉, 吴定中, 张惠勇, 邱磊.
清咳平喘颗粒治疗支气管扩张症的回顾性临床研究.
中草药,
2025
, 56
(9)
: 3197
-3202
.
DOI: 10.7501/j.issn.0253-2670.2025.09.017
FAN Yaxin, BAI Ping, WANG Yu, MA Shuangshuang, ZHANG Yemin, BI Rongrong, WU Dingzhong, ZHANG Huiyong, QIU Lei.
Retrospective clinical study on Qingke Pingchuan Granules in treatment of bronchiectasis[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(9)
: 3197
-3202
.
DOI: 10.7501/j.issn.0253-2670.2025.09.017
Year 2025 volume 56 Issue 9
39
8
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.09.017
- Receive Date:2024-11-28
- Online Date:2026-11-13